Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Public ClinicalTrials.gov record NCT06191744. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world. Participants will receive R2 (intravenous \[IV\] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) \[G-CHOP\]/ R-CHOP or G and IV infusion of bendamustine (Benda) \[G-Benda\]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study identification
- NCT ID
- NCT06191744
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,095 participants
Conditions and interventions
Conditions
Interventions
- Epcoritamab Drug
- Prednisone Drug
- Rituximab Drug
- Lenalidomide Drug
- Doxorubicin Drug
- Vincristine Drug
- Cyclophosphamide Drug
- Obinutuzumab Drug
- Bendamustine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2024
- Primary completion
- Oct 31, 2037
- Completion
- Oct 31, 2037
- Last update posted
- Aug 3, 2026
2024 – 2037
United States locations
- U.S. sites
- 58
- U.S. states
- 25
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Fresno /ID# 264712 | Fresno | California | 93701-2302 | — |
| Scripps Mercy Hospital /ID# 265393 | San Diego | California | 92103 | — |
| Sansum Clinic Research /ID# 261596 | Santa Barbara | California | 93105 | — |
| Rocky Mountain Cancer Centers - Boulder /ID# 261203 | Boulder | Colorado | 80303 | — |
| Christiana Care Health Service /ID# 261207 | Newark | Delaware | 19713 | — |
| Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445 | Jacksonville | Florida | 32256 | — |
| Advent Health /ID# 261578 | Orlando | Florida | 32803 | — |
| Orlando Health Cancer Institute /ID# 260983 | Orlando | Florida | 32806 | — |
| Moffitt Cancer Center /ID# 259487 | Tampa | Florida | 33612-9416 | — |
| Beacon Cancer Care - Coeur d'Alene /ID# 260670 | Coeur d'Alene | Idaho | 83814 | — |
| Northwestern Medicine - Northwestern Memorial Hospital /ID# 259814 | Chicago | Illinois | 60611 | — |
| Cancer Care Specialists Of Central Illinois /ID# 272464 | Decatur | Illinois | 62526 | — |
| Loyola University /ID# 259462 | Maywood | Illinois | 60153 | — |
| Illinois Cancer Care, PC /ID# 261526 | Peoria | Illinois | 61615 | — |
| Fort Wayne Medical Oncology and Hematology- South Office /ID# 259583 | Fort Wayne | Indiana | 46804 | — |
| University of Iowa Health Care /ID# 262132 | Des Moines | Iowa | 50314-3017 | — |
| University of Louisville Hospital /ID# 260544 | Louisville | Kentucky | 40202 | — |
| Norton Cancer Institute - St. Matthews /ID# 261076 | Louisville | Kentucky | 40207 | — |
| New England Cancer Specialists - Westbrook /ID# 260672 | Westbrook | Maine | 04092 | — |
| University of Maryland, Baltimore /ID# 259538 | Baltimore | Maryland | 21201 | — |
| Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 259476 | Bethesda | Maryland | 20817 | — |
| St. Luke's Hospital - Chesterfield /ID# 260489 | Chesterfield | Missouri | 63017 | — |
| Intermountain Health St Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006 | Billings | Montana | 59102 | — |
| Nebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506 | Grand Island | Nebraska | 68803 | — |
| Nebraska Hematology-Oncology /ID# 269692 | Lincoln | Nebraska | 68506 | — |
| Nebraska Cancer Specialists - Omaha - Wright Street /ID# 262505 | Omaha | Nebraska | 68130 | — |
| University of Nebraska Medical Center /ID# 261996 | Omaha | Nebraska | 68198 | — |
| University of New Mexico /ID# 261083 | Albuquerque | New Mexico | 87102-4517 | — |
| Presbyterian Kaseman Hospital /ID# 262451 | Albuquerque | New Mexico | 87110 | — |
| Presbyterian Rust Medical Center /ID# 262447 | Rio Rancho | New Mexico | 87124 | — |
| New York Oncology Hematology - Albany Cancer Center /ID# 261814 | Albany | New York | 12206-5013 | — |
| NYU Langone Hospital - Long Island /ID# 265531 | Mineola | New York | 11501 | — |
| NYU Langone Medical Center /ID# 264518 | New York | New York | 10016-6402 | — |
| Icahn School of Medicine at Mount Sinai /ID# 259595 | New York | New York | 10029 | — |
| New York Oncology Hematology /ID# 270208 | Troy | New York | 12180 | — |
| Clinical Research Alliance - Westbury /ID# 261078 | Westbury | New York | 11590 | — |
| Novant Health Presbyterian Medical Center /ID# 259740 | Charlotte | North Carolina | 28204 | — |
| Novant Health Forsyth Medical Center /ID# 259741 | Winston-Salem | North Carolina | 27103 | — |
| Oncology Hematology Care, Inc - Blue Ash /ID# 261204 | Cincinnati | Ohio | 45252 | — |
| Taylor Cancer Research Center /ID# 260488 | Maumee | Ohio | 43537-1921 | — |
| Oncology Associates of Oregon, P.C. /ID# 261816 | Eugene | Oregon | 97401 | — |
| MUSC Hollings Cancer Center /ID# 259604 | Charleston | South Carolina | 29425 | — |
| Prisma Health /ID# 259602 | Greenville | South Carolina | 29605 | — |
| Sarah Cannon Research Institute - Tristar Centennial Medical Center /ID# 274985 | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Austin Midtown /ID# 261208 | Austin | Texas | 78705 | — |
| Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 261206 | Dallas | Texas | 75246-2003 | — |
| MD Anderson Cancer Center /ID# 260984 | Houston | Texas | 77030-4000 | — |
| Oncology Consultants /ID# 268390 | Houston | Texas | 77030 | — |
| Joe Arrington Cancer Research /ID# 260382 | Lubbock | Texas | 79410 | — |
| Intermountain Healthcare LDS Hospital /ID# 259759 | Salt Lake City | Utah | 84143 | — |
| Virginia Cancer Specialists - Fairfax /ID# 261205 | Fairfax | Virginia | 22031 | — |
| Oncology and Hematology Associates of Southwest Virginia /ID# 261592 | Roanoke | Virginia | 98684 | — |
| Swedish Cancer Institute - Edmonds /ID# 266356 | Edmonds | Washington | 98026 | — |
| Swedish Cancer Institute - Issaquah /ID# 266358 | Issaquah | Washington | 98029 | — |
| Vista Oncology - East Olympia /ID# 261360 | Olympia | Washington | 98506-5028 | — |
| Virginia Mason Hospital and Medical Center /ID# 260549 | Seattle | Washington | 98101 | — |
| Swedish Medical Center - Seattle /ID# 260370 | Seattle | Washington | 98104 | — |
| Northwest Medical Specialties - Tacoma /ID# 262133 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 208 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06191744, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 3, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06191744 live on ClinicalTrials.gov.